Tag: Dr Kari Nadeau

COUR Pharma Pipeline

COUR Announces First In-Human Dosing in Proof-of-Concept Trial of CNP-201 to...

CNP-201 is a nanoparticle containing peanut protein that aims to eliminate allergic responses.
COVID-19 Vaccine Vials

Study: PEG Linked to Rare Allergic Reactions to mRNA COVID-19 Vaccines

An ingredient used in many products including lotions and shampoos, may be the cause of rare allergic reactions to the mRNA COVID-19 vaccines.
COUR Nanoparticle

FDA Accepts Investigational New Drug Application for Novel Peanut Allergy Therapy

The company, which is already in phase 2 clinical trials with a treatment for celiac disease, has announced the FDA has accepted their Investigational New Drug (IND) application for evaluation of CNP-201, A treatment for peanut allergy. that reduces the need for strict peanut avoidance and reduces the potentially fatal health risks associated with peanut allergy.
Clinical Trial

Broad Spectrum OIT Candidate for Multiple Food Allergies Begins Phase 1/2...

The Harmony Study plans to enroll patients across 20 sites in the United States.
Peanuts

How Much Peanut Does it Take to Trigger an Allergic Reaction?

UC toxicologist says finding an ‘eliciting dose’ may help some who have food allergies.
Twins Study

Twins Study Identifies Fecal Microbiome Differences in Food Allergies

By transplanting fecal microbes from healthy and food-allergic infants to germ-free mice (who do not possess a microbiome), investigators found that the healthy infant microbiota was protective against the development of food allergies.
Dr Kari Nadeau - Keynote Speaker at FARE Research Retreat

Watch: Dr Kari Nadeau Discusses Food Allergy Prevention and Treatment at...

Well worth your time if you have food allergies, care for someone who does, or are pregnant or considering pregnancy in the near future.
2020 Contains Courage Research Retreat

FARE Announces 2020 Contains: Courage® Research Retreat

Virtual two-day event to feature guest appearance by Dr. Anthony Fauci and sessions open to public for the first time ever.
IgG Antibody

Company Developing Therapy to Prevent “Allergic Cascade” Emerges from Stealth Mode

IgGenix will develop a therapy that focuses on all types of food allergies and related conditions.
Alladapt

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development...

Company is developing therapy to target a number of food allergies simultaneously.